Tatva Chintan Pharma Chem Limited
NSE:TATVA.NS
856.35 (INR) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|---|---|
Revenue
| 3,935.04 | 4,236.12 | 4,312.93 | 2,968.57 | 2,576.85 | 2,024.49 | 1,337 |
Cost of Revenue
| 2,545.48 | 2,261.01 | 2,076.78 | 1,554.66 | 1,384.4 | 1,163.01 | 1,015.41 |
Gross Profit
| 1,389.56 | 1,975.11 | 2,236.15 | 1,413.91 | 1,192.45 | 861.48 | 321.59 |
Gross Profit Ratio
| 0.353 | 0.466 | 0.518 | 0.476 | 0.463 | 0.426 | 0.241 |
Reseach & Development Expenses
| 79.42 | 60.39 | 37.07 | 2.79 | 10.14 | 1.99 | 1.89 |
General & Administrative Expenses
| 58.9 | 50.67 | 43.84 | 22.93 | 22.74 | 39.53 | 0 |
Selling & Marketing Expenses
| 225.13 | 287.66 | 338.26 | 191.88 | 170.23 | 159.21 | 0 |
SG&A
| 963.65 | 404.76 | 382.1 | 214.81 | 192.97 | 198.74 | 132.62 |
Other Expenses
| 75.09 | 57.44 | 1.33 | 4.5 | 453.13 | 0.39 | -2.04 |
Operating Expenses
| 963.65 | 1,464.85 | 1,228.22 | 807.89 | 656.24 | 541.05 | 136.55 |
Operating Income
| 425.91 | 584.69 | 1,004.84 | 601.81 | 532.5 | 317 | 185.04 |
Operating Income Ratio
| 0.108 | 0.138 | 0.233 | 0.203 | 0.207 | 0.157 | 0.138 |
Total Other Income Expenses Net
| 9.77 | -139.04 | 36.37 | 3.95 | -56.53 | -43.07 | 5.3 |
Income Before Tax
| 435.68 | 447.79 | 1,041.21 | 606.96 | 475.97 | 273.93 | 190.34 |
Income Before Tax Ratio
| 0.111 | 0.106 | 0.241 | 0.204 | 0.185 | 0.135 | 0.142 |
Income Tax Expense
| 132.14 | -7.08 | 82.47 | 84.34 | 98.08 | 68.5 | 67.45 |
Net Income
| 303.54 | 454.87 | 958.74 | 522.62 | 377.89 | 205.43 | 122.89 |
Net Income Ratio
| 0.077 | 0.107 | 0.222 | 0.176 | 0.147 | 0.101 | 0.092 |
EPS
| 13.26 | 20.52 | 44.59 | 26.02 | 18.81 | 10.23 | 6.12 |
EPS Diluted
| 13.26 | 20.52 | 44.59 | 26.02 | 18.81 | 10.23 | 6.12 |
EBITDA
| 681.96 | 663.25 | 1,166.14 | 714.69 | 562.18 | 339.42 | 214.56 |
EBITDA Ratio
| 0.173 | 0.157 | 0.27 | 0.241 | 0.218 | 0.168 | 0.16 |